 Therapy ischemic cardiomyopathy pentoxifylline Abnormal blood rheology known characteristics coronary artery disease authors effects pentoxifylline exercise capacity ejection fraction symptoms patients ischemic cardiomyopathy patients signs symptoms left ventricular dysfunction major vessels coronary angiography mg times twelve weeks Seven patients increases ejection fraction exercise tolerance Exercise tolerance improvement lack improvement ejection fraction patients twelve weeks post-therapy mean ejection fraction baseline total treadmill time mean double product Anginal symptoms baseline twelve weeks therapy dyspnea exertion Pentoxifylline Pentoxifylline ischemic cardiomyopathy coronary perfusion favorable alterations hemorheologic properties